

BRAWN BIOTECH LIMITED
(formerly known as Brawn Pharmaceuticals Limited)
CIN: L74899DL1985PLC022468
REGD. OFFICE: C-64, LAJPAT NAGAR-I, NEW DELHI-110024

Part I		(Rs in Lacs)					
Statement of Standalone Unaudited Results for the Quarter ended 31/12/2015							
S. No.	PARTICULARS	Quarter Ended	Quarter Ended	Quarter Ended	Nine Months Ended	Nine Months Ended	Year Ended
		31.12.2015	30.09.2015	31.12.2014	31.12.2015	31.12.2014	31.03.2015
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	Income from Operations						
a.	Net Sales/ Income from operations (Net of Excise Duty)	1,247.20	1,218.77	1,147.67	3,424.06	3,021.57	3,798.08
b.	Other Operating Income	24.09	23.24	18.53	64.00	48.26	66.56
	Total income from operations (Net)	1,271.28	1,242.01	1,166.20	3,488.06	3,069.83	3,864.64
2	Expenses						
a.	Cost of materials Consumed	-	-	-	-	-	-
b.	Purchase of Stock in Trade	1,087.69	1,093.60	1,048.47	2,994.00	2,645.80	3,332.58
c.	Change in Inventories of Finished Goods, work-in-Progress and Stock-in-Trade	29.14	(12.35)	(6.94)	36.63	67.16	68.31
d.	Employee Benefits Expenses	51.36	40.67	38.69	126.23	107.40	151.82
e.	Depreciation and amortisation expenses	0.94	0.94	0.81	2.76	2.37	2.62
f.	Other Expenditure	71.78	79.59	70.16	207.59	216.90	256.20
	Total Expenses	1,240.91	1,202.45	1,151.19	3,367.21	3,039.63	3,811.53
3	Profit/ (loss) from Operations before Other Income, Finance Cost and Exceptional Items (1-2)	30.37	39.56	15.01	120.85	30.20	53.11
4	Other Income	2.99	-	-	3.38	1.58	5.18
5	Profit/ (Loss) from ordinary activities before Finance Cost and Exceptional Items (3+4)	33.36	39.56	15.01	124.23	31.78	58.29
6	Finance Cost	1.69	1.40	0.21	3.28	0.82	10.45
7	Profit/ (Loss) from ordinary activities after Finance Cost but before Exceptional Items (5+6)	31.67	38.16	14.80	120.95	30.96	47.84
8	Exceptional Items	-	-	-	-	-	-
9	Profit(+)/Loss(-) from Ordinary Activities before tax (7+8)	31.67	38.16	14.80	120.95	30.96	47.84
10	Tax Expenses (Provisions)	8.03	-	6.40	8.03	9.47	19.41
11	Net Profit (+)/ Loss (-) from Ordinary Activities after tax (9-10)	23.64	38.16	8.40	112.92	21.49	28.43
12	Extraordinary Items (net of tax expenses)	-	-	-	-	-	-
13	Net Profit(+)/ Loss(-) for the period (11-12)	23.64	38.16	8.40	112.92	21.49	28.43
14	Paid-up equity share capital (Face Value of the Share is Rs.10/- each)	300.03	300.03	300.03	300.03	300.03	300.03
15	Reserve excluding Revaluation Reserves as per balance sheet of previous accounting year	306.63	282.99	187.21	306.63	187.21	193.71
16 i	Earnings Per Share (before extraordinary items)(not annualised):in Rs.						
(a)	Basic	0.79	1.27	0.28	3.76	0.72	0.95
(b)	Diluted	0.79	1.27	0.28	3.76	0.72	0.95
16 ii	Earnings Per Share (after extraordinary items)(not annualised):in Rs.						
(a)	Basic	0.79	1.27	0.28	3.76	0.72	0.95
(b)	Diluted	0.79	1.27	0.28	3.76	0.72	0.95

Note:

- The above Unaudited financial results have been reviewed by the Audit Committee and taken on record by the board of the directors at their meeting held on 12.02.2016.
- There are no reportable segments other than pharmaceuticals as per As-17 on Segment Reporting.
- The Statutory Auditors have carried out a limited review of the above Financial Results.
- The previous period/ year figures have been regrouped/ re-arranged, wherever necessary to confirm to the current period's classification.

For and on behalf of the Board

Place: New Delhi
Date: 12-02-2016

Sd/-
(Director)